WeChat Mini Program
Old Version Features

Development and Validation of an LC-MS/MS Method for Simultaneous Determination of SH-1028, an Irreversible Third-Generation EGFR TKI, and Two of Its Metabolites in Human Plasma: Application in Clinical Pharmacokinetics

Xenobiotica; the fate of foreign compounds in biological systems(2023)SCI 4区

Nanjing Med Univ

Cited 0|Views26
Abstract
SH-1028 is a novel, potent, and highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed for the treatment of T790M Mutation-positive non-small cell lung cancer (NSCLC). The objective was to develop an LC-MS/MS method for the simultaneous determination of SH-1028 and its metabolites, Imp2 and Imp3, in human plasma.The plasma samples were extracted through protein precipitation with acetonitrile on wet ice conditions. A rapid, sensitive, and specific method was developed and successfully applied to evaluate the pharmacokinetic (PK) properties of SH-1028 in patients with advanced NSCLC following single and multiple doses of SH-1028 (60 mg).After single-dose administration, the C-max of SH-1028, Imp2, and Imp3 was 11.2, 50.2, and 7.99 ng/mL, respectively. The mean AUC(0-24 h) was 138, 602, and 76.7 h*ng/mL, respectively. And the terminal half-life time was 19.9, 14.4, and 26.1 h, respectively. After multiple-dose administration, SH-1028 exhibited a slight accumulation, with a mean accumulation ratio (R-AUC) of 2.00.The study assessed the PK properties of SH-1028 following single and multiple doses in patients with advanced NSCLC and would provide meaningful information for the further development of SH-1028.
More
Translated text
Key words
SH-1028,LC-MS,MS,human plasma,EGFR-TKIs,pharmacokinetics
求助PDF
上传PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:本文开发并验证了一种液相色谱-串联质谱(LC-MS/MS)方法,用于同时测定人血浆中的SH-1028及其两个代谢物,并应用于临床药代动力学研究,创新点在于实现了第三代不可逆EGFR抑制剂SH-1028及其代谢物在血浆中的快速、灵敏和特异性检测。

方法】:采用乙腈在湿冰条件下进行蛋白质沉淀以提取血浆样本,并利用LC-MS/MS技术进行SH-1028及其代谢物Imp2和Imp3的定量分析。

实验】:研究了晚期NSCLC患者在单次和多次剂量(60 mg)SH-1028给药后的药代动力学特性,实验数据集为患者血浆样本,结果显示单次给药后SH-1028及其代谢物的Cmax、AUC(0-24 h)和终末半衰期分别为11.2 ng/mL、138 hng/mL、19.9 h;50.2 ng/mL、602 hng/mL、14.4 h;7.99 ng/mL、76.7 h*ng/mL、26.1 h,多次给药后SH-1028表现出轻微积累,平均积累比为2.00。